Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 7, 2026 to Discuss Your Rights - INO

Core Viewpoint - Inovio Pharmaceuticals, Inc. is facing a class action lawsuit for alleged securities law violations, with claims that the company made materially false and misleading statements regarding its manufacturing processes and regulatory prospects for its lead product candidate, INO-3107 [1]. Group 1: Allegations - The lawsuit alleges that Inovio's manufacturing for the CELLECTRA device was deficient [1]. - It is claimed that Inovio is unlikely to submit its lead product candidate, INO-3107 BLA, to the FDA by the second half of 2024 [1]. - The company reportedly lacked sufficient information to justify INO-3107's eligibility for FDA accelerated approval or priority review [1]. - Consequently, the overall regulatory and commercial prospects of INO-3107 were overstated [1]. - As a result, the defendants' public statements were materially false and misleading throughout the relevant period [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as October 10, 2023, to December 26, 2025 [1]. - Shareholders are encouraged to register for the class action by April 7, 2026, to discuss their rights and potential recovery [1]. - There is no cost or obligation for shareholders to participate in the case [1].